journal article·2023-07Open access

Endogenous dual miRNA-triggered dynamic assembly of DNA nanostructures for in-situ dual siRNA delivery

Wukun Zhong, Lei Huang, Yuhong Lin, Chao Xing, Chunhua Lu

Science China Materials· Volume 66· Issue 7

Abstract

A theranostic strategy of multiple microRNA (miRNA)-triggered in-situ delivery of small interfering RNA (siRNA) can effectively improve the precise therapy of cancer cells. Benefiting from the advantages of programmability, specific molecular recognition, easy functionalization and marked biocompatibility of DNA nanostructures, we designed a three-dimensional (3D) DNA nano-therapeutic platform for dual miRNA-triggered in-situ delivery of siRNA. The 3D DNA nanostructure (TY1Y2) was constructed based on the self-assembly of a DNA tetrahedra scaffold, two sets of Y-shaped DNA (Y1 and Y2), and EpCAM-aptamer which functionalized as the ligand molecule for the recognition of specific cancer cells. After being specifically internalized into the targeted cancer cells, TY1Y2 was triggered by two endogenous miRNAs (miR-21 and miR-122), resulting in the generation of strong fluorescence resonance energy transfer fluorescent signal for dual miRNAs imaging. Meanwhile, the therapeutic siRNAs (siSurvivin and siBcl2) could also be in-situ generated and released from TY1Y2 through the strand-displacement reactions for the synergistic gene therapy of cancer cells. This 3D DNA nanostructure integrated the specific imaging of endogenous biomarkers and the in-situ delivery of therapeutic genes into the multifunctional nanoplatform, revealing the promising applications for the diagnosis and treatment of cancer. Electronic supplementary material Supplementary material is available in the online version of this article at 10.1007/s40843-022-2420-y.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · MXene and MAX Phase Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (34)

Show source-provided references
1. Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol, 2006, 2: 711–71910.1038/nchembio839 ↗
2. Setten RL, Rossi JJ, Han S. Author correction: The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov, 2020, 19: 29010.1038/s41573-019-0027-2 ↗
3. Shen S, Dean DC, Yu Z, et al. Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067. J Cancer, 2020, 11: 132–14110.7150/jca.35426 ↗
4. Kim B, Park JH, Sailor MJ. Rekindling RNAi therapy: Materials design requirements for in vivo siRNA delivery. Adv Mater, 2019, 31: 190363710.1002/adma.201903637 ↗
5. Jiang Q, Yue S, Yu K, et al. Endogenous microRNA triggered enzymefree DNA logic self-assembly for amplified bioimaging and enhanced gene therapy via in situ generation of siRNAs. J Nanobiotechnol, 2021, 19: 28810.1186/s12951-021-01040-x ↗
6. Hyun S, Choi Y, Lee HN, et al. Construction of histidine-containing hydrocarbon stapled cell penetrating peptides for in vitro and in vivo delivery of siRNAs. Chem Sci, 2018, 9: 3820–382710.1039/C8SC00074C ↗
7. Koppers-Lalic D, Hogenboom MM, Middeldorp JM, et al. Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Adv Drug Deliver Rev, 2013, 65: 348–35610.1016/j.addr.2012.07.006 ↗
8. Idris A, Davis A, Supramaniam A, et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther, 2021, 29: 2219–222610.1016/j.ymthe.2021.05.004 ↗
9. He X, Yin F, Wang D, et al. AIE featured inorganic-organic core@shell nanoparticles for high-efficiency siRNA delivery and real-time monitoring. Nano Lett, 2019, 19: 2272–227910.1021/acs.nanolett.8b04677 ↗
10. Lin S, Xie P, Luo M, et al. Efficiency against multidrug resistance by co-delivery of doxorubicin and curcumin with a legumain-sensitive nanocarrier. Nano Res, 2018, 11: 3619–363510.1007/s12274-017-1928-1 ↗
11. Gong X, Li R, Wang J, et al. A smart theranostic nanocapsule for spatiotemporally programmable photo-gene therapy. Angew Chem Int Ed, 2020, 59: 21648–2165510.1002/anie.202008413 ↗
12. Li D, Li X, Yang F, et al. Targeted delivery of DNA framework-encapsulated native therapeutic protein into cancer cells. ACS Appl Mater Interfaces, 2020, 12: 54489–5449610.1021/acsami.0c17887 ↗
13. Dong Y, Yao C, Zhu Y, et al. DNA functional materials assembled from branched DNA: Design, synthesis, and applications. Chem Rev, 2020, 120: 9420–948110.1021/acs.chemrev.0c00294 ↗
14. Wang Z, Song L, Liu Q, et al. A tubular DNA nanodevice as a siRNA/chemo-drug co-delivery vehicle for combined cancer therapy. Angew Chem Int Ed, 2021, 60: 2594–259810.1002/anie.202009842 ↗
15. Mou Q, Ma Y, Ding F, et al. Two-in-one chemogene assembled from drug-integrated antisense oligonucleotides to reverse chemoresistance. J Am Chem Soc, 2019, 141: 6955–696610.1021/jacs.8b13875 ↗
16. Pang L, Shah H, Wang H, et al. EpCAM-targeted 3WJ RNA nanoparticle harboring delta-5-desaturase siRNA inhibited lung tumor formation via DGLA peroxidation. Mol Ther Nucleic Acids, 2020, 22: 222–23510.1016/j.omtn.2020.08.024 ↗
17. Xiao D, Li Y, Tian T, et al. Tetrahedral framework nucleic acids loaded with aptamer AS1411 for siRNA delivery and gene silencing in malignant melanoma. ACS Appl Mater Interfaces, 2021, 13: 6109–611810.1021/acsami.0c23005 ↗
18. Li C, Zhou J, Wu Y, et al. Core role of hydrophobic core of polymeric nanomicelle in endosomal escape of siRNA. Nano Lett, 2021, 21: 3680–368910.1021/acs.nanolett.0c04468 ↗
19. Moore GWK, Howell SEL, Brady M, et al. Anomalous collapses of nares strait ice arches leads to enhanced export of arctic sea ice. Nat Commun, 2021, 12: 110.1038/s41467-020-20314-w ↗
20. Chen L, Li G, Wang X, et al. Spherical nucleic acids for near-infrared light-responsive self-delivery of small-interfering RNA and antisense oligonucleotide. ACS Nano, 2021, 15: 11929–1193910.1021/acsnano.1c03072 ↗
21. Daugaard I, Hansen TB. Biogenesis and function of Ago-associated RNAs. Trends Genet, 2017, 33: 208–21910.1016/j.tig.2017.01.003 ↗
22. Farh KKH, Grimson A, Jan C, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science, 2005, 310: 1817–182110.1126/science.1121158 ↗
23. Hill M, Tran N. Global miRNA to miRNA interactions: Impacts for miR-21. Trends Cell Biol, 2021, 31: 3–510.1016/j.tcb.2020.10.005 ↗
24. Tavakolizadeh J, Roshanaei K, Salmaninejad A, et al. MicroRNAs and exosomes in depression: Potential diagnostic biomarkers. J Cell Biochem, 2018, 119: 3783–379710.1002/jcb.26599 ↗
25. Ren K, Zhang Y, Zhang X, et al. In situ siRNA assembly in living cells for gene therapy with microRNA triggered cascade reactions templated by nucleic acids. ACS Nano, 2018, 12: 10797–1080610.1021/acsnano.8b02403 ↗
26. Yue R, Chen M, Ma N. Dual microRNA-triggered drug release system for combined chemotherapy and gene therapy with logic operation. ACS Appl Mater Interfaces, 2020, 12: 32493–3250210.1021/acsami.0c09494 ↗
27. Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer, 2019, 19: 553–56710.1038/s41568-019-0180-2 ↗
28. Chen X, Chen T, Zhang L, et al. Cyclodextrin-mediated formation of porous RNA nanospheres and their application in synergistic targeted therapeutics of hepatocellular carcinoma. Biomaterials, 2020, 261: 12030410.1016/j.biomaterials.2020.120304 ↗
29. Hemphill J, Deiters A. DNA computation in mammalian cells: MicroRNA logic operations. J Am Chem Soc, 2013, 135: 10512–1051810.1021/ja404350s ↗
30. Quan K, Li J, Wang J, et al. Dual-microRNA-controlled double-amplified cascaded logic DNA circuits for accurate discrimination of cell subtypes. Chem Sci, 2019, 10: 1442–144910.1039/C8SC04887H ↗
31. Liu L, Li N, Huang ZM, et al. Gold nanoflares with computing function as smart diagnostic automata for multi-miRNA patterns in living cells. Anal Chem, 2020, 92: 10925–1092910.1021/acs.analchem.0c02325 ↗
32. Martínez-García D, Manero-Rupérez N, Quesada R, et al. Therapeutic strategies involving survivin inhibition in cancer. Med Res Rev, 2019, 39: 887–90910.1002/med.21547 ↗
33. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest, 2001, 108: 981–99010.1172/JCI200112983 ↗
34. Perini GF, Ribeiro GN, Pinto Neto JV, et al. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol, 2018, 11: 6510.1186/s13045-018-0608-2 ↗